文献速递真菌感染细菌感染、耐药与抗菌药物

侵袭性念珠菌病早期(≤5天)棘白菌素降阶梯至唑类治疗的前瞻性评估

Evaluation of an early step-down (≤5 days) strategy from echinocandins to azole therapy for the treatment of invasive candidiasis.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

单中心前瞻性研究纳入114例侵袭性念珠菌病患者,比较早期(≤5天)棘白菌素降阶梯至唑类(DES)与持续棘白菌素治疗。DES组治疗结束时临床成功率和生存率更高,但30天全局应答无统计学差异;在念珠菌血症亚组中DES改善30天应答,且大幅降低抗真菌费用。

要点

  • 早期DES在临床稳定且感染源控制的IC患者中安全,不增加不良结局。
  • DES组治疗结束时临床成功率更高(79.4% vs 58.8%,P=0.017)。
  • 念珠菌血症亚组中DES改善30天应答(65.1% vs 43.2%,P=0.049)。

核心结论

  • 在临床稳定且感染源控制的侵袭性念珠菌病患者中,早期(≤5天)棘白菌素降阶梯至唑类是安全的,且与更差的结局无关,支持在抗菌药物管理项目中使用。

研究设计与样本

  • 单中心前瞻性研究,为期17个月,纳入152例筛选患者中的114例成人侵袭性念珠菌病(80例念珠菌血症,34例腹腔内念珠菌病),接受初始棘白菌素治疗。
  • 比较早期(≤5天)降阶梯(DES)与持续棘白菌素治疗(非DES),采用逆概率治疗加权(IPTW)调整基线差异。

主要发现

  • DES组30天全局应答为60.3%,非DES组为45.1%(P=0.105),差异无统计学意义。
  • DES组治疗结束时临床成功率为79.4%,非DES组为58.8%(P=0.017);治疗结束时死亡率为11.1% vs 29.4%(P=0.014)。
  • IPTW调整后,DES与30天全局应答改善无显著关联。
  • 念珠菌血症亚组中,DES组30天应答为65.1%,非DES组为43.2%(P=0.049);腹腔内念珠菌病亚组无差异。
  • 早期DES使每例念珠菌血症 episode 的抗真菌费用降低77.4%。

关键数值与推荐

  • DES组55.3%患者接受降阶梯,其中95.2%转为氟康唑,降阶梯中位时间为4天。

临床怎么用

  • 对于临床稳定且感染源已控制的侵袭性念珠菌病患者,可考虑早期(≤5天)将棘白菌素降阶梯至氟康唑,以降低费用并支持抗菌药物管理。
  • 念珠菌血症患者可能从早期降阶梯中获益更多,但需结合临床稳定性与感染源控制情况个体化决策。

局限性

  • 单中心前瞻性研究,样本量有限(114例),结果需更大规模研究验证。
  • 30天全局应答差异未达统计学显著性,IPTW调整后DES与30天应答改善无显著关联。
  • 降阶梯策略主要在临床稳定且感染源控制的患者中实施,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Invasive candidiasis (IC) carries high mortality; although guidelines recommend echinocandins followed by de-escalation (DES) to azoles in stable patients, the optimal timing, particularly for early (≤5 days) step-down, remains uncertain due to limited prospective evidence. This study evaluates the safety and outcomes of early (≤5 days) antifungal de-escalation (DES) versus standard therapy. METHODS: Single-centre prospective study during 17 months in adults with candidemia or intra-abdominal candidiasis (IAC) receiving initial echinocandin therapy. Early (≤5 days) DES was compared with continued echinocandin therapy (non-DES). The primary outcome was 30-day global response; secondary outcomes included mortality at end of treatment (EoT), recurrence, length of stay, microbiological outcomes and antifungal consumption/costs. Inverse probability of treatment weighting (IPTW) was applied to adjust for baseline differences between groups. RESULTS: Of 152 screened patients, 114 with IC (80 candidemia, 34 IAC) were included; 55.3% underwent DES, mainly to fluconazole (95.2%), at a median of 4 days. The 30-day global response was higher with DES but not statistically significant (60.3% versus 45.1%, P = 0.105). However, DES was associated with higher clinical success at EoT (79.4% versus 58.8%, P = 0.017) and lower EoT mortality (11.1% versus 29.4%, P = 0.014). After IPTW adjustment, DES was not associated with improved 30-day global response. In candidemia, DES improved 30-day response (65.1% versus 43.2%, P = 0.049), whereas no differences were observed in IAC. Early DES reduced antifungal costs by 77.4% per /candidemia episode. CONCLUSIONS: Early DES in clinically stable IC patients with source control was safe and not associated with worse outcomes, supporting its use in stewardship programmes.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Albanell-Fernández M, Tuset M, Vergara A, et al. Evaluation of an early step-down (≤5 days) strategy from echinocandins to azole therapy for the treatment of invasive candidiasis. J Antimicrob Chemother. 2026. PMID: 42535271. doi:10.1093/jac/dkag252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。